Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Christoph Saal"'
Autor:
Joerg Schlingemann, Michael J. Burns, David J. Ponting, Carolina Martins Avila, Naiffer E. Romero, Mrunal A. Jaywant, Graham F. Smith, Ian W. Ashworth, Stephanie Simon, Christoph Saal, Andrzej Wilk
Publikováno v:
Journal of Pharmaceutical Sciences. 112:1287-1304
This article reports the outcome of an in silico analysis of more than 12,000 small molecule drugs and drug impurities, identifying the nitrosatable structures, assessing their potential to form nitrosamines under relevant conditions and the challeng
Autor:
Bertil Abrahamsson, James Butler, Rodrigo Cristofoletti, Christos Reppas, Edmund Kostewicz, Christoph Saal
Publikováno v:
Journal of Pharmaceutical Sciences. 111:14-17
Publikováno v:
Journal of Pharmaceutical Sciences. 112:1161-1162
Autor:
Felix Ditzinger, Daniel J. Price, Anita Nair, Johanna Becker-Baldus, Clemens Glaubitz, Jennifer B. Dressman, Christoph Saal, Martin Kuentz
Publikováno v:
Pharmaceutics, Vol 11, Iss 11, p 577 (2019)
Amorphous formulation technologies to improve oral absorption of poorly soluble active pharmaceutical ingredients (APIs) have become increasingly prevalent. Currently, polymer-based amorphous formulations manufactured by spray drying, hot melt extrus
Externí odkaz:
https://doaj.org/article/84d04692b34543d8b7058a540fcff24f
Autor:
Christoph Saal
Publikováno v:
Solid State Development and Processing of Pharmaceutical Molecules. :449-480
Autor:
Joerg Schlingemann, Celine Boucley, Sebastian Hickert, Laura Bourasseau, Matt Walker, Caroline Celdran, Thibaut Chemarin, Celine Pegues, Matthias Fritzsche, Judith Keitel, Anja Goettsche, Maic Seegel, Stefan Leicht, Brunhilde Guessregen, Philipp Reifenberg, Stephanie Wetzel, Tim Müller, Fanny Schooren, Tobias Schuster, Mike Liebhold, Annette Kirsch, Phillip Krueger, Christoph Saal, Bruno Mouton, Sandra Masanes
Publikováno v:
International journal of pharmaceutics. 620
Since late 2019, concerns regarding trace levels of the probable human carcinogen N-dimethylnitrosamine (NDMA) in Metformin-containing pharmaceuticals have been an issue if they exceeded the maximum allowable intake of 96 ng/day for a medicine with l
Autor:
Annette Kirsch, Matthias Fritzsche, Joerg Schlingemann, Christoph Saal, Romane Baranowski, Emmanuel Desmartin, Nicholas O'Neill, Maic Seegel, Tony Bristow, Mark Harrison, Phillip Krueger, Giorgio Blom, Anja Goettsche, Brunhilde Guessregen, Philipp Reifenberg, Sebastian Hickert, Alexandra Cimelli, Stefan Leicht, Bruno Mouton, Elodie Barrau, Judith Keitel
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 168
Background For nearly three years, the concerns regarding trace levels of N-nitrosamines in pharmaceuticals and the associated cancer risk have significantly expanded and are a major issue facing the global pharmaceutical industry. N-nitrosodimethyla
Autor:
Jochem Alsenz, Patrick Augustijns, Kiyohiko Sugano, German L. Perlovich, Maria Vertzoni, Christos Reppas, Joachim Brouwers, A Müllerz, Cas Bergström, Annette Bauer-Brandl, Christoph Saal
Publikováno v:
Vertzoni, M, Alsenz, J, Augustijns, P, Bauer-Brandl, A, Bergström, C A S, Brouwers, J, Müllerz, A, Perlovich, G, Saal, C, Sugano, K & Reppas, C 2022, ' UNGAP best practice for improving solubility data quality of orally administered drugs ', European Journal of Pharmaceutical Sciences, vol. 168, 106043 . https://doi.org/10.1016/j.ejps.2021.106043
An important goal of the European Cooperation in Science and Technology (COST) Action UNGAP (UNderstanding Gastrointestinal Absorption-related Processes, www.ungap.eu) is to improve standardization of methods relating to the study of oral drug absorp
Publikováno v:
Journal of pharmaceutical sciences. 111(1)
Low solubility of drugs represents a major challenge during research and development. Ways to overcome this are either focused on formulation development or optimization of the molecular structure of the drug. The latter is not only governed by the c
Publikováno v:
Journal of pharmaceutical sciences. 110(5)
New drug candidates often require bio-enabling formation technologies such as lipid-based formulations, solid dispersions, or nanosized drug formulations. Development of such more sophisticated delivery systems generally requires higher resource inve